99Mtc-It-rituximab: an Effective Radiotracer for Identifying Sentinel Lymph Nodes in Breast Cancer

Xuejuan Wang,Bei Lin,Zhi Yang,Tao Ouyang,Jingfeng Li,Xu Bing,Meiying Zhang

2006-01-01

Abstract:1647 Objectives: To characterize the effects of 99mTc-IT-rituximab for locating SLN, and tested its feasibility as a lymphoscintigraphic agent in breast cancer patients. Methods: Rituximab was radiolabeled with 99mTc by way of the bifunctional chelator 2-iminothiolane (2-IT). The immunological integrity of 99mTc-IT-rituximab was evaluated by SDS-PAGE, ELISA and flow-cytometric analysis (FCA). The biological property and safety limitation of 99mTc-IT-rituximab was studied according to China Pharmacopoeia. Eighty-five breast cancer cases, including one with bilateral breast cancer, were studied. Lymphoscintigraphy was performed after peritumor and intradermal injection of 99mTc-IT-rituximab, and was followed by high-count images of the SLN. Eighty-five cases with breast cancer underwent sentinel lymph node biopsy (SLNB) directed by vital blue dye mapping and the gamma probe. All SLNs were examined by H&E staining and immunohistochemistry method. Results: 99mTc-IT-rituximab was proved to have the similar immunological character with rituximab by SDS-PAGE, ELISA and FCA. 99mTc-IT-rituximab was free of bacteria, pyogen free and toxicity. 99mTc-IT-rituximab was mainly excreted by kidney. High kidney uptake was found for 99mTc-IT-rituximab at 1 h, its uptake at each time point was (14.01±0.61)%/g, (9.81±0.61) %/g, (5.64±0.77) %/g and (3.51±0.48) %/g. Other tissues exhibited less than 1 percent of the injected dose at all time points. In ten patients with breast cancer, the results of dynamic SLN mapping show that SLN could be seen within a wide range from 30 min to 24 h postinjection 99mTc-IT-rituximab. The higher order nodes had not been seen all the time. Draining lymphatic basins and nodes were imaged by lymphoscintigraphy in 82 cases of eighty-five. The SLN was identified in 96.5 % (82/85) of patients when both blue dye and intraoperative gamma probe were used. Thirty cases of SLN (36.6%) were metastasis positive, including 24 positive cases by H&E staining and 6 by immunohistochemistry method. SLN was the only metastasis lymph node in 18 out of 30 cases. One case has negative SLN metastasis. The sensitivity and accuracy of SLNB were 96.8% (30/31) and 98.8% (81/82). The specificity was 100% (51/51). The false negative rate was 3.3 (1/31) and the negative predictive value was 98.1 (51/52). The positive predictive value was 100% (31/31). Conclusions: 99mTc-IT-Rituximab appears to be potential and useful for clinical SLN study.